vs
STANDARD BIOTOOLS INC.（LAB）与Simulations Plus, Inc.（SLP）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是Simulations Plus, Inc.的1.1倍（$19.6M vs $18.4M），Simulations Plus, Inc.净利率更高（3.7% vs -177.4%，领先181.1%），Simulations Plus, Inc.同比增速更快（-2.7% vs -11.5%），过去两年Simulations Plus, Inc.的营收复合增速更高（0.3% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
Simulations Plus公司为医药生物、化工、化妆品、食品原料及除草剂领域开发ADMET（吸收、分布、代谢、排泄和毒性）建模仿真软件，并于2014年9月收购了提供临床试验数据分析及咨询服务的Cognigen公司，助力相关行业研发工作开展。
LAB vs SLP — 直观对比
营收规模更大
LAB
是对方的1.1倍
$18.4M
营收增速更快
SLP
高出8.8%
-11.5%
净利率更高
SLP
高出181.1%
-177.4%
两年增速更快
SLP
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $18.4M |
| 净利润 | $-34.7M | $676.0K |
| 毛利率 | 48.5% | 59.1% |
| 营业利润率 | -168.5% | 3.9% |
| 净利率 | -177.4% | 3.7% |
| 营收同比 | -11.5% | -2.7% |
| 净利润同比 | -28.8% | 228.2% |
| 每股收益（稀释后） | $-0.09 | $0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABSLP
| Q4 25 | — | $18.4M | ||
| Q3 25 | $19.6M | $17.5M | ||
| Q2 25 | $21.8M | $20.4M | ||
| Q1 25 | $40.8M | $22.4M | ||
| Q4 24 | — | $18.9M | ||
| Q3 24 | $22.1M | $18.7M | ||
| Q2 24 | $22.5M | $18.5M | ||
| Q1 24 | $45.5M | $18.3M |
净利润LABSLP
| Q4 25 | — | $676.0K | ||
| Q3 25 | $-34.7M | $-681.0K | ||
| Q2 25 | $-33.5M | $-67.3M | ||
| Q1 25 | $-26.0M | $3.1M | ||
| Q4 24 | — | $206.0K | ||
| Q3 24 | $-26.9M | $843.0K | ||
| Q2 24 | $-45.7M | $3.1M | ||
| Q1 24 | $-32.2M | $4.0M |
毛利率LABSLP
| Q4 25 | — | 59.1% | ||
| Q3 25 | 48.5% | 56.4% | ||
| Q2 25 | 48.8% | 64.0% | ||
| Q1 25 | 48.4% | 58.5% | ||
| Q4 24 | — | 54.0% | ||
| Q3 24 | 54.9% | 36.6% | ||
| Q2 24 | 46.1% | 71.5% | ||
| Q1 24 | 53.1% | 72.2% |
营业利润率LABSLP
| Q4 25 | — | 3.9% | ||
| Q3 25 | -168.5% | 3.8% | ||
| Q2 25 | -118.1% | -364.5% | ||
| Q1 25 | -80.8% | 12.1% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | -120.9% | -6.2% | ||
| Q2 24 | -134.5% | 10.1% | ||
| Q1 24 | -132.2% | 24.3% |
净利率LABSLP
| Q4 25 | — | 3.7% | ||
| Q3 25 | -177.4% | -3.9% | ||
| Q2 25 | -153.7% | -330.6% | ||
| Q1 25 | -63.8% | 13.7% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | -122.0% | 4.5% | ||
| Q2 24 | -203.3% | 16.9% | ||
| Q1 24 | -70.6% | 22.0% |
每股收益（稀释后）LABSLP
| Q4 25 | — | $0.03 | ||
| Q3 25 | $-0.09 | $-0.03 | ||
| Q2 25 | $-0.09 | $-3.35 | ||
| Q1 25 | $-0.07 | $0.15 | ||
| Q4 24 | — | $0.01 | ||
| Q3 24 | $-0.07 | $0.04 | ||
| Q2 24 | $-0.12 | $0.15 | ||
| Q1 24 | $-0.27 | $0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $35.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $127.1M |
| 总资产 | $539.6M | $137.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABSLP
| Q4 25 | — | $35.7M | ||
| Q3 25 | $129.4M | $32.4M | ||
| Q2 25 | $158.6M | $28.4M | ||
| Q1 25 | $150.9M | $21.4M | ||
| Q4 24 | — | $18.2M | ||
| Q3 24 | $210.6M | $20.3M | ||
| Q2 24 | $269.8M | $119.0M | ||
| Q1 24 | $287.1M | $108.5M |
总债务LABSLP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABSLP
| Q4 25 | — | $127.1M | ||
| Q3 25 | $399.7M | $124.8M | ||
| Q2 25 | $424.5M | $123.8M | ||
| Q1 25 | $454.6M | $189.5M | ||
| Q4 24 | — | $184.7M | ||
| Q3 24 | $489.3M | $182.4M | ||
| Q2 24 | $510.3M | $180.9M | ||
| Q1 24 | $577.3M | $177.0M |
总资产LABSLP
| Q4 25 | — | $137.8M | ||
| Q3 25 | $539.6M | $131.9M | ||
| Q2 25 | $557.0M | $134.4M | ||
| Q1 25 | $579.6M | $201.4M | ||
| Q4 24 | — | $196.9M | ||
| Q3 24 | $681.5M | $196.6M | ||
| Q2 24 | $708.7M | $192.7M | ||
| Q1 24 | $777.7M | $194.0M |
负债/权益比LABSLP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $4.2M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | — |
| 自由现金流率自由现金流/营收 | -118.1% | — |
| 资本支出强度资本支出/营收 | 4.5% | 0.0% |
| 现金转化率经营现金流/净利润 | — | 6.26× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | — |
8季度趋势，按日历期对齐
经营现金流LABSLP
| Q4 25 | — | $4.2M | ||
| Q3 25 | $-22.2M | $5.6M | ||
| Q2 25 | $-20.7M | $8.1M | ||
| Q1 25 | $-30.3M | $5.7M | ||
| Q4 24 | — | $-1.3M | ||
| Q3 24 | $-27.9M | $1.7M | ||
| Q2 24 | $-39.0M | $5.7M | ||
| Q1 24 | $-62.5M | $5.8M |
自由现金流LABSLP
| Q4 25 | — | — | ||
| Q3 25 | $-23.1M | $5.3M | ||
| Q2 25 | $-22.6M | $7.8M | ||
| Q1 25 | $-35.3M | $5.6M | ||
| Q4 24 | — | $-1.4M | ||
| Q3 24 | $-30.1M | $1.6M | ||
| Q2 24 | $-41.0M | $5.6M | ||
| Q1 24 | $-63.3M | $5.4M |
自由现金流率LABSLP
| Q4 25 | — | — | ||
| Q3 25 | -118.1% | 30.5% | ||
| Q2 25 | -103.6% | 38.5% | ||
| Q1 25 | -86.6% | 25.0% | ||
| Q4 24 | — | -7.2% | ||
| Q3 24 | -136.4% | 8.8% | ||
| Q2 24 | -182.2% | 30.0% | ||
| Q1 24 | -138.9% | 29.4% |
资本支出强度LABSLP
| Q4 25 | — | 0.0% | ||
| Q3 25 | 4.5% | 1.5% | ||
| Q2 25 | 8.7% | 1.5% | ||
| Q1 25 | 12.4% | 0.3% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | 10.2% | 0.1% | ||
| Q2 24 | 8.6% | 0.6% | ||
| Q1 24 | 1.7% | 2.4% |
现金转化率LABSLP
| Q4 25 | — | 6.26× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.84× | ||
| Q4 24 | — | -6.18× | ||
| Q3 24 | — | 1.97× | ||
| Q2 24 | — | 1.81× | ||
| Q1 24 | — | 1.44× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
SLP
| Services Segment | $9.5M | 52% |
| Development | $7.2M | 39% |
| Discovery | $1.3M | 7% |
